Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10033536 | 0.80 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL7276909 | 0.80 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTALOX12TSHR | |
| SCHEMBL11096615 | 0.79 | BACE1 (0.31) | KDM4E | |
| SCHEMBL7270574 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTALOX12TSHR | |
| SCHEMBL28004701 | 0.75 | ALDH1A1 (0.33) | ALDH1A1KDM4E | |
| SCHEMBL27410529 | 0.72 | ALDH1A1 (0.36) | ALDH1A1KDM4EMAPT | |
| SCHEMBL230068 | 0.71 | ALDH1A1 (0.50) | ALDH1A1KDM4EMAPT | |
| SCHEMBL3816284 | 0.70 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTALOX12TSHR | |
| SCHEMBL9843658 | 0.70 | ALDH1A1 (0.38) | ALDH1A1MAPT | |
| SCHEMBL2861221 | 0.70 | ALDH1A1 (0.38) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632953-B2 | Process for the preparation of gabalactam | HIKAL LIMITED (IN) | 2009-12-15 | — | — | US | disclosed |
| EP-1599446-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | HIKAL LTD (IN) | 2009-08-12 | — | — | EP | disclosed |
| US-20060135789-A1 | Process for the preparation of gabalactam | HIKAL LIMITED | 2006-06-22 | — | — | US | disclosed |
| EP-1599446-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | Hikal Ltd. (IN) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004046108-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF GABALACTAM | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135789-A1 | Process for the preparation of gabalactam | GABRA5, GABRB1, GABRA6 | ALDH1A1 49/4885KDM4E 134/4885MAPT 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.